Conexeu Sciences Inc.: management transactions · United States · SEC (Form 4)

About Conexeu Sciences Inc.

Conexeu Sciences Inc. (ticker: CXNU) is a U.S.-based, pre-commercial medtech company listed on the NASDAQ market in the United States. For European investors, the company should be viewed as an early-stage regenerative medicine story with a highly speculative risk profile and meaningful upside optionality if regulatory and development milestones are achieved. Conexeu was incorporated on November 2, 2022, and later domesticated into Nevada in April 2025. Its principal executive office is in Reno, Nevada, and its strategic focus is the development of collagen-based tissue regeneration products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2066836/000106299326002473/form424b4.htm)) The company’s origin lies in intellectual property developed over more than a decade at the University of British Columbia and the BC Professional Firefighters Burn and Wound Healing Laboratory. Conexeu acquired the relevant patent rights in November 2023, enabling it to move the asset from an academic setting toward a staged industrial development program. Its only disclosed product candidate is CXU™, an ECM scaffold device candidate built on a proprietary collagen platform. Importantly, CXU is still in preclinical development and has not been approved or cleared for sale in any jurisdiction, which places the investment case firmly in the category of clinical, regulatory and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2066836/000106299326002473/form424b4.htm)) From a competitive standpoint, Conexeu is targeting the advanced wound care and regenerative medicine markets, where established players typically benefit from deeper clinical evidence, broad reimbursement pathways and stronger commercial infrastructure. Conexeu’s stated differentiators are its patent estate and its platform approach. The company says it holds patent protection in the United States, Europe, Japan and Australia, with expiry currently indicated around February 2036, while some manufacturing know-how remains protected as trade secrets. Management also indicates that the collagen platform could eventually support multiple indications, including wound care, dentistry, veterinary applications, aesthetics and 3D tissue constructs, subject to further development and regulatory approvals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2066836/000106299326002473/form424b4.htm)) Recent developments have centered on corporate build-out and capital formation. In 2025, Conexeu appointed Miles Harrison as President and CEO and brought in Claudia Chavez-Munoz as Chief Science Officer, strengthening both commercial and scientific leadership. The company also expanded its development program to include manufacturing process development, supplier qualification, biocompatibility testing, regulatory strategy work and formal design/documentation processes. In May 2026, Conexeu disclosed the exercise of warrants that generated approximately $1.96 million in gross proceeds, a reminder that funding remains an ongoing priority for a company still advancing toward first regulatory submissions. Overall, CXNU remains a high-risk NASDAQ-listed U.S. healthcare name best suited to investors comfortable with early-stage biotech/medtech volatility. ([nasdaq.com](https://www.nasdaq.com/press-release/conexeu-sciences-appoints-miles-harrison-president-chief-executive-officer-shape))